R&D, transparency key to sustained private label gains
This article was originally published in The Tan Sheet
Executive SummaryPrivate labelers must innovate and work closely with retailers to survive investments by national brands looking to win back market share, according to a panel convened by the Private Label Manufacturers Association. The panel - including Taro Pharmaceuticals VP of OTC Products Ed Moniz and Perrigo Consumer Healthcare VP of OTC Marketing Ron Schutt - discussed post-recession strategies for private label marketers. Despite the recent success of store brands, retailers are hesitant to commit to private label suppliers for the long term, which could stifle research and development investments by those firms, according to the panel report PLMA released Sept. 1. Additionally, national players are launching value brands and line extensions as direct challenges to private label, the trade group says. PLMA's panel recommends private labelers make their operations more transparent to retail chains, which now require more value-added benefits from their store brand products
You may also be interested in...
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.
Medicaid programs are essentially getting Humira for free, in large part because of price inflation rebates, according to estimates by Bernstein analysts. Legislation pending in the US Senate wants to bring that dynamic to Medicare.